Genetics and Genomics in Clinical Medicine

Slides:



Advertisements
Similar presentations
Drug Information for Consumers and Healthcare Professionals Food and Drug Law Institute Annual Meeting Alan Goldhammer, PhD Associate VP Regulatory Affairs.
Advertisements

Association of Schools of Allied Health Professions Conference Healthcare Research, Now and Beyond the Horizon Dr. Ken Shine October 19, 2005.
1 Intermountain Healthcare Clinical Genetics Institute Marc S. Williams, M.D. Director Grant M. Wood Senior IT Strategist Introduction to HL7 Clinical.
Ronald T. Ackermann, MD, MPH Indiana University School of Medicine
National Health Policy Conference, Washington, DC February 6, Drug Safety Challenges: Considerations for Sources of Data Gerald J. Dal Pan, MD,
Taking Research and Development to the Clinic: Issues for Physicians AAAS/FDLI Colloquium I Diagnostics and Diagnoses Paths to Personalized Medicine Howard.
Health IT and Personalized Medicine Policy Implications John Glaser, PhD Senior Advisor, ONC/HHS Vice President and CIO Partners HealthCare October 26,
THE COMMONWEALTH FUND 1 Doctors Use Electronic Patient Medical Records* * Not including billing systems. Percent Source: 2009 Commonwealth Fund International.
Figure 1. Rating the U.S. Health System Scores on major dimensions of system performance Source: Commonwealth Fund National Scorecard on U.S. Health System.
Connecting California: The Role of State Leadership in Advancing Health Information Technology CCST Board and Council Meeting Molly Coye, MD, MPH Chair,
Warfarin, Insulin and Digoxin are the most Dangerous drugs in the elderly. Do we believe that?
Ellen Andrews, PhD For the eHealth Privacy and Security Forum, State Capitol, Hartford eHealth Why consumers should care.
Gilead’s Tech Transfer Partnerships and IP in India
Don’t take my word for it
Educational Event 23rd & 24th January 2013
©PPRNet 2014 Impact of Patient Engagement on Treatment Decisions and Patient-Centered Outcomes in the Implementation of New Guidelines for the Treatment.
Genomic Medicine: A Revolution in Medical Practice in the 21 st Century Francis S. Collins, M.D., Ph.D. National Human Genome Research Institute World.
The Importance of Individual Patient Response in Clinical Trials Group 8: Zhiyuan Xu, Yiwen Zhang, Chelsea Nichols, Lu Wang, Nadir Demirel, Travis Myers.
The views and statements expressed here are provided for informational purposes and do not necessarily reflect those of Medivo, the Alliance for Continuing.
POC INR Testing Rural and Remote Session 2015 CADTH SYMPOSIUM Janice Mann MD Knowledge Mobilization, CADTH.
Project IMPACT IMPACT National Medical Association What African Americans Should Know About Clinical Trials You’ve Got the Power!
Clinical Information Systems HINF Medical Methodologies Session 5.
Past, Present, Future December 6, 2004 Past, Present, Future December 6, 2004 Physicians, Hospitals and the Evolution of Electronic Medical Records (EMR)
Healthy People 2010 Focus Area 17: Medical Product Safety Progress Review October 19, 2007.
Medical Database By: Emily Michels Ben Pruitt November 27, 2006.
Clinical Genotyping and Personalized Medicine Michael D. Kane, PhD (1) Associate Professor of Bioinformatics (2) University Faculty Scholar (3) Chair of.
Importance of Pharmacogenetics in Oncology Richard Pazdur, MD. Director Office of Oncology Drug Products Center for Drug Evaluation and Research Food and.
Personalized Medicine
An overview of off-label drug use Ignoring the Label Samantha Rue.
Implementation of a Hospital Paediatric Antimicrobial Stewardship Program Sydney Children’s Hospital Mostaghim M, Snelling T, McMullan B, Palasanthiran.
Kenneth Sisco, MD, PhD, FCAP Medical Director Quest Diagnostics
University of Utah Department of Human Genetics Pharmacogenomics Louisa A. Stark, Ph.D. Director.
Managing Warfarin Drug Interactions: The Bayview Experience DAWN Users Group, November 2002 Charles H. Twilley, MBA, PharmD Johns Hopkins Bayview Medical.
Antiplatelet or Anticoagulant: Do They Have the same Efficacy? University of Central Florida Deborah Andrews RN, BSN.
Introduction to Precision Medicine
Dr.F Eslamipour DDS.MS Orthodontist Associated professor Department of Oral Public Health Isfahan University of Medical Science.
Preventing Surgical Complications Prevent Harm from High Alert Medication- Anticoagulants in Primary Care Insert Date here Presenter:
K NOWLEDGE S ERVICE E XPERIENCE Integrated Clinical Solutions.
Stop the Clot ™ David Henry and Tom Hogan Cardiovascular and Renal Drugs Advisory Committee U.S. Food and Drug Administration Adelphi,
Biomedical Research.
CMS as a Public Health Agency: Effective Health Care Research Barry M. Straube, M.D. Centers for Medicare & Medicaid Services January 11, 2006.
Instrumenting the Healthcare Enterprise for Discovery Opening Remarks James Mongan, MD President and CEO Partners HealthCare April 11, 2008.
DVT Prevention and Anticoagulant Management
Developing medicines for the future and why it is challenging Angela Milne.
Breaking the Code Information Technology, Genomics, and the Journey Toward Personalized Medicine.
Anticoagulants Reducing the risk Amanda Powell & Sue Wooller May 2014.
Focus Area 17: Medical Product Safety Progress Review November 5, 2003.
Preventing Errors in Medicine
BDH Discovering Tomorrow’s Healthcare Solutions Today Clinical Research Services, Inc. Basil Halliday, M.Sc. President & CEO BDH Clinical Research Services.
Pharmacogenetics.
Integrating Pharmacogenomic Questions Into GCIG Ovarian Cancer Clinical Trials Lori Minasian, MD Chief, Community Oncology and Prevention Trials Research.
Challenges to drug design Did you know? Over 2 million people are hospitalized each year for adverse reactions to prescription drugs. Over 2 million.
Impact of Multidisciplinary Team Care on Older People with Polypharmacy Liang-Kung Chen Center for Geriatrics and Gerontology Taipei Veterans General Hospital.
Applying New Science to Drug Safety Janet Woodcock, M.D. Acting Deputy Commissioner for Operations April 15, 2005.
Pharmacogenomics: Improving the Dynamic of Care in Medication Management 1.
Medication errors Debbie Cruickshank ICU Pharmacist Life The Glynnwood.
Given the progress that continues to be made in society’s battle against disease, patients are seeking more information about medical problems and potential.
Technology of healthcare  BY: seemeka Johnson. Technology of healthcare Doctors now know that genetics play a part in possibly passing on diseases from.
Pharmacogenomics based personalized medicine: Are the standards of evidence requirements different from standards for Clinical-Based Personalized Medicine?
Viagra (sildenafil citrate): Extensive Clinical and Post-Marketing Experience Michael Sweeney, MD Senior Medical Director Pfizer Inc.
European Patients’ Academy on Therapeutic Innovation Challenges in Personalised Medicine.
Moiz Bakhiet, MD, PhD, Professor and Chairman
Semantic Web - caBIG Abstract: 21st century biomedical research is driven by massive amounts of data: automated technologies generate hundreds of.
Strategies to Modernize State Medicaid Programs, Utah’s Medicaid Transformation By Lisa V. Hulbert R.Ph. Transformation Program Manager Utah Medicaid.
You’ve Got the Power! What African Americans Should Know About Clinical Trials National Medical Association.
Aug, 2016.
Pragmatic RCTs and the Learning Healthcare System
Pharmacogenomics Genes and Drugs.
Only 28% of U.S. Primary Care Physicians Have Electronic Medical Records; Only 19% Advanced IT Capacity, 2006 Percent reporting 7 or more out of 14 functions*
COMPUTERIZED PHYSICIAN ORDER ENTRY (CPOE)
Presentation transcript:

Genetics and Genomics in Clinical Medicine Raju Kucherlapati, Ph.D. Harvard Medical School Partners Healthcare

GENETICS AND GENOMICS CAN HELP Healthcare Issues Healthcare costs are rising rapidly Costs of drug development at all time high Estimated cost of a new drug 800 MM Drugs are not effective in all patients Some cancer drugs are effective in less than 20% of patients Drug related adverse events are a major cause of ER visits Even when drugs are effective severe adverse reactions can cause major problems GENETICS AND GENOMICS CAN HELP

National Thought Leaders on Personalized Medicine “I believe we are moving into a remarkable and powerful new era in medicine and particularly in prescription drugs. I’d refer to it as an era of personalized medicine.” Michael Leavitt, Secretary HHS January 18, 2005

What is Personalized Medicine? The right drug or treatment, at the right time, for the right patient, at the right cost everytime Personalized medicine requires genetic or other type of testing How fast the test results are available becomes critical

Future of Medical Care A revolution in medical practice and care has to take place Personalized Medicine is a part of this revolution Some would consider the notion of Personalized Medicine to be similar to many earlier disruptive technologies such as color television and personal computers Implementation of Personalized Medicine would require changes in many paradigms that include More discoveries Effectiveness Support of Regulatory agencies Positive cost/benefit ratio Rapid test results Physician and Public Education Effective IT support to manage and interpret results

Discoveries are becoming more rapid August 2007 Genome-Wide Association Analysis Identifies Loci for Type 2 Diabetes and Triglyceride Levels Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical Research et al

Effectiveness Effectiveness can be measured by clinical data Retrospective studies Prospective clinical trials Examples of a prospective clinical trails For new drugs – Herceptin, Gleevec For approved drugs - Warfarin

Genetics of Warfarin dosing More than 20 million prescriptions of Warfarin every year and 2 million new patients/year are prescribed Warfarin. It is the most effective oral anticoagulant drug Warfarin anticoagulation is prescribed to achieve a target INR. Excessive dosing precipitates hemorrhage. Inadequate dosing predisposes to stroke and pulmonary embolism. Dosing nomograms work poorly. Trial and error predominates. CYP 2C9 VKORC1 Genotype Dose Haplotype Dose *1/*1 7.2 mg A/A 2.7 mg *1/*2 4.1 mg A/B 4.9 mg *1/*3 *2/*2 1.4 mg B/B 6.2 mg *2/*3 *3/*3 We are now conducting a clinical trial to test the hypothesis

Regulatory Activity PERSONAL DOSE In Milestone, FDA Pushes Genetic Tests Tied to Drug Agency Seeks to Tame Risks of Blood Thinner; Some Doctors Protest By ANNA WILDE MATHEWS August 16, 2007; Page A1 August 16, 2007  

FDA Approves Label Change for Warfarin FDA Approves Genetic Testing Labeling For Blood-thinning Drug August 18, 2007 "Today's approved labeling change is one step in our commitment to personalized medicine. By using modern science to get the right drug in the right dose for the right patient, FDA will further enhance the safety and effectiveness of the medicines Americans depend on," Andrew C. von Eschenbach, M.D. Commissioner of FDA

Cost/Benefit Analysis for Warfarin testing “We estimate that formally integrating genetic testing into routine warfarin therapy could allow American warfarin users to avoid 85,000 serious bleeding events and 17,000 strokes annually. We estimate the reduced health care spending from integrating genetic testing into warfarin therapy to be $1.1 billion annually, with a range of about $100 million to $2 billion.” Andrew McWilliam, Randall Lutter and Clark Nardinelli Office of Policy and Planning at the FDA AEI-BROOKINGS JOINT CENTER FOR REGULATORY STUDIES November 2006

Time to Getting Test Results For Warfarin testing turn around times are 7-10 days Too late for clinical dosing decisions Need to have answers within 24 hours, preferably a few hours Ideal situation is POC diagnostic or a local lab that provides results fast Need to get the result into the electronic medical record Need to provide a dosing recommendation We now provide Warfarin test results within 24 hours

Genetic data in EMR

Test Results in EMR

First Genetics Based Clinical Decision Support Rule

Personalized Healthcare The Ultimate Goal Clinical data Personalized Healthcare Genetic variation Megabytes – Gigabytes of Data Per Patient Genetic expression The patient has disease X, subclass Y, which will likely respond to drug Z Proteomic expression